SEMAGLUTIDE Peptide – User Manual & Dosage Protocol Guide

Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist peptide studied for its role in glycemic control, weight management, and appetite regulation.

Research Applications:

• Supporting blood sugar regulation and insulin sensitivity
• Reducing appetite and caloric intake
• Supporting weight management studies
• Investigating metabolic health and cardiovascular benefits

Disclaimer: Semaglutide is for research and experimental use only. It is not FDA-approved for non-research purposes. Consult a qualified healthcare professional before use.

Product Form

Lyophilized Powder – Freeze-dried Semaglutide for reconstitution

Injection Solution – Subcutaneous (SC) solution after reconstitution

Pre-filled Pens – Research-use only; ready-to-use injections

Semaglutide functions by:

• Activating GLP-1 receptors in the pancreas and brain
• Stimulating insulin secretion and reducing glucagon release
• Slowing gastric emptying, enhancing satiety
• Supporting weight reduction and metabolic regulation

Effects are primarily studied in research and experimental protocols.

Administration

Subcutaneous (SC) Injection – Typical Dose: 0.25–2.4 mg | Frequency: Once weekly | Notes: Gradual titration recommended to reduce gastrointestinal side effects

Pre-filled Pens – Typical Dose: 0.25–2.4 mg | Frequency: Once weekly | Notes: Ready-to-use dosing; follow research protocol for titration

Titration Example (Investigational)

Week 1–4 – Dose: 0.25–0.5 mg/week | Notes: Initial titration to assess tolerance

Week 5–8 – Dose: 1.0 mg/week | Notes: Intermediate dose for research objectives

Week 9–12 – Dose: 1.7–2.4 mg/week | Notes: Target maintenance dose for study purposes

Titration helps minimize side effects such as nausea, vomiting, or mild gastrointestinal discomfort.

Supplies Needed:

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

Steps:

1. Clean vial top with alcohol swab.
2. Add desired volume of bacteriostatic water (e.g., 1 mg peptide + 1 mL water → 1 mg/mL solution).
3. Swirl gently to dissolve; do not shake.
4. Store refrigerated (2–8°C).
5. Use within 2–4 weeks; discard if cloudy or discolored.

Subcutaneous Injection (SC)

1. Select clean injection site (abdomen, thigh, or upper arm).
2. Clean site with alcohol swab.
3. Insert needle at 45° angle.
4. Inject slowly; apply gentle pressure afterward.
5. Rotate injection sites weekly to prevent irritation.

Pre-filled Pen Administration

• Follow pen instructions for dose selection and injection.
• Inject once weekly at consistent times.
• Rotate injection sites to avoid tissue irritation.

Lyophilized Powder – Storage: Cool, dry place | Shelf Life: Up to 12 months

Reconstituted Solution – Storage: Refrigerate 2–8°C | Shelf Life: 2–4 weeks

Pre-filled Pens – Storage: Refrigerate 2–8°C | Shelf Life: 1–2 months after first use

Discard solution if cloudy, discolored, or containing particulates.

• Not for pregnant or breastfeeding women
• Avoid if allergic to GLP-1 analogs or peptide components
• Common side effects: nausea, vomiting, diarrhea, mild headache
• Discontinue if severe adverse reactions occur
• Keep out of reach of children

Human clinical data exist for medical uses, but research protocols may differ. All investigational use should follow safety monitoring.

Weekly Cycle ScheduleWeek 1–4 – Dose: 0.25–0.5 mg/week SC | Notes: Initial titration phase

Week 5–8 – Dose: 1.0 mg/week SC | Notes: Intermediate dose

Week 9–12 – Dose: 1.7–2.4 mg/week SC | Notes: Maintenance/target dose

Week 13+ – Dose: Rest or continuation | Notes: Per research protocol

• Diagrams of SC injection sites (abdomen, thigh, upper arm)
• Step-by-step reconstitution guide
• Pre-filled pen usage instructions
• Safety icons for handling, storage, and injections